Becton, Dickinson and Company BDXB
At closeMay 31, 2023, 4:00 PM EDT
- Market cap
- 13.69B
- Revenue (ttm)
- 18.81B
- Profit margin
- 8.60%
- EPS (ttm)
- 6.33
- P/E ratio
- 7.60
- Dividend
- 3.00 (5.78%)
- Ex-dividend date
- Aug 11, 2021
- Volume
- 2.76M
- Avg volume
- 449.58K
- Open
- 47.20
- Previous close
- 48.16
- Day's range
- 47.65 – 48.82
- 52-week range
- 45.85 – 52.52
- Beta
- 0.56
Key statistics
- Enterprise value
- 29.92B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.53
- Dividend yield
- 5.78%
- Payout ratio
- 0.00%
- Revenue growth
- 1.50%
- Free cash flow
- 1.76B
- Total cash
- 1.99B
- Total debt
- 18.22B
- Return on equity
- 6.56%
- Short % of float
- 0.00%
- 50-day average
- 49.93
- 200-day average
- 49.31
Next earnings
Consensus EPS estimate 0.00.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- bd.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on BDXB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bank Of New York Mellon Corporation | 0.00% | 1,159,168 | 55.83M | Mar 30, 2023 |
| American Century Companies, Inc. | 0.00% | 3,997,703 | 192.53M | Mar 30, 2023 |
| Blackrock Inc. | 0.00% | 2,290,001 | 110.29M | Mar 30, 2023 |
| Camden Asset Management L P /ca | 0.00% | 1,308,400 | 63.01M | Mar 30, 2023 |
| Franklin Resources, Inc. | 0.00% | 606,920 | 29.23M | Mar 30, 2023 |
| Capital World Investors | 0.00% | 5,647,202 | 271.97M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Washington Mutual Investors Fund | 0.00% | 2,963,696 | 142.73M | Mar 30, 2023 |
| American Century Equity Income | 0.00% | 2,799,928 | 134.84M | Dec 30, 2022 |
| Income Fund of America Inc | 0.00% | 2,467,280 | 118.82M | Mar 30, 2023 |
| iShares Preferred & Income Securities ETF | 0.00% | 2,251,882 | 108.45M | Feb 27, 2023 |
| Price (T.Rowe) Equity Income Fund | 0.00% | 1,320,000 | 63.57M | Dec 30, 2022 |
| Franklin Investors Securities Trust-Equity Income Fund | 0.00% | 600,000 | 28.90M | Jan 30, 2023 |
